NIOME Targets 100 Million Genomic Datasets as Its Research Network Expands

NIOME (SN55) has revealed that it is working with the Scottish government on a partnership that will use its genomics infrastructure and AI research capabilities to study bacterial genomic strains.

Speaking on Hash Rate Pod, Aldo de Pape of NIOME (SN55) and Genomes.io noted that the subnet is currently setting up the partnership with a government-backed organization in Scotland. The organization has collected bacterial genomic strains and is looking for both a secure way to store that information and more advanced ways to research it. Aldo described NIOME as potentially one of the first Bittensor subnets with a government partnership tied directly to its commercial growth.

The work expands NIOME beyond human genomics. Bacteria also carry genomic information, and studying different strains can help researchers better understand diseases they cause. Under the planned setup, the genomic information could be secured using Genomes.io’s infrastructure, while NIOME and its bioinformatics team would provide the AI layer for further research.

NIOME is built around generating synthetic genomic information for pharmaceutical companies, biotech firms and researchers. Synthetic data can preserve useful genomic patterns without being directly tied to a real individual, giving researchers another way to work with large datasets while reducing some of the privacy concerns surrounding real patient information.

The subnet has already generated more than 10 million synthetic genomic datasets and is targeting roughly 100 million by the end of the year. It also has 24 research challenges planned through the end of 2027, focused on different genetic diseases, conditions and areas of genomic research.

According to Aldo, Bittensor has been a major accelerator for the company because of the amount of compute required to operate at that scale. When asked whether NIOME could have generated its first 10 million datasets as efficiently without Bittensor, he said that, as far as he could see, it could not.

That infrastructure is also becoming part of NIOME’s commercial model. Pharmaceutical and biotech companies can use its datasets directly, license access to its database, or potentially dedicate the subnet’s miners to proprietary research problems. Aldo said larger research engagements could command six-figure prices, with a client effectively using the subnet’s compute for several months to investigate a specific question.

NIOME is also working with organizations that already own valuable genomic or other biological datasets. Those datasets can be synthesized and incorporated into dedicated nodes, allowing them to participate in future AI research while creating another commercial route for the original data owners.

The goal is to make NIOME part of the development process for genetic medicines. Aldo said traditional genetic research can take years and cost tens of millions of dollars before researchers even reach a therapeutic candidate. The team believes AI, synthetic genomic data and distributed compute can make that process faster and considerably cheaper.

The Scottish government partnership now gives NIOME a practical opportunity to apply that infrastructure to real genomic research, while also showing how a Bittensor subnet can build commercial relationships outside the crypto ecosystem.

➛ Read On NIOME (SN55)’s Partnership With University of Aberdeen: